WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended October 1, 2023. Third quarter financial summary Revenues of $746.4 million, up 8.7% compared to the prior year period; up 7.4% on a constant currency basis GAAP diluted EPS […]
Other News
Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System
GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Revascularization in Stroke) clinical study. MARRS is a multi-center trial to evaluate the performance of the Millipede System. The first patient was enrolled at Stony Brook University Hospital in Stony Brook, NY. “I am delighted to begin enrollment in the MARR
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Nov. 1, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the last of four Late-Breaking Clinical Trial sessions at the VIVA23…
Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it has entered into a definitive agreement to acquire LimFlow, S.A., a […]
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Nov. 1, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four Late-Breaking Clinical Trial sessions at the VIVA23…
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure TEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIANS […]
Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ — Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. (“Heartseed”), a Tokyo-based biotechnology…
Covera Health Announces Up to $50M in Additional Series C Funding to Redefine the Role of Radiology Nationwide
Company Expands Industry’s Most Sophisticated AI-Enabled Radiology Performance Platform with Acquisition of CoRead NEW YORK, Nov. 1, 2023 /PRNewswire/ — Covera Health, the leading AI-enabled diagnostic technology company focused on radiology performance measurement and impact, today…
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
LONDON–(BUSINESS WIRE)—- $SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L and stable atherosclerotic cardiova
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23
LAS VEGAS, Oct. 31, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four Late-Breaking Clinical Trial sessions at the…
Recent
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Popular
- No commented posts yet